文献速递痛风与晶体性关节病

英国英格兰地区COVID-19大流行期间痛风发病率与管理:基于OpenSAFELY的全英国观察性研究

Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELY.
PubMed 文献 · Lancet Rheumatol · 2023-08-31

该研究利用OpenSAFELY平台分析英格兰1786万成人电子健康记录,评估COVID-19大流行对痛风发病率和管理质量的影响。结果显示2020年3月起一年内痛风新诊断下降30.9%,住院下降30.1%,但降尿酸治疗处方略有改善,血尿酸达标率相似。

要点

  • 2020年3月起一年痛风新诊断较前一年下降30.9%(每1000成人1.23 vs 1.78)。
  • 同期痛风住院下降30.1%(每10万成人9.6 vs 13.7)。
  • 6个月内启动降尿酸治疗者占29.2%,达标(≤360 μmol/L)者占25.7%。

核心结论

  • 以痛风为例显示COVID-19大流行期间医疗服务影响的复杂性,观察到痛风诊断减少但治疗指标无影响。

研究设计与样本

  • 基于OpenSAFELY平台的人口水平队列研究,纳入英格兰使用TPP软件的全科诊所中1786万145名18-110岁成人,研究期为2015年3月1日至2023年2月28日。

主要发现

  • 从参考人群1786万5145成人中,246695人被诊断为痛风新发;平均年龄61.3岁(SD 16.2),女性66265/246695(26.9%),男性180430/246695(73.1%),白人189035/208050(90.9%)。
  • 2020年3月起一年痛风新诊断较前一年下降30.9%(每1000成人1.23 vs 1.78),痛风患病率2015-16年为3.07%,2022-23年为3.21%。
  • 2020年3月起一年痛风住院较前一年下降30.1%(每10万成人9.6 vs 13.7)。
  • 228095例新发痛风且有随访者中66560例(29.2%)在6个月内接受降尿酸治疗;65305例启动降尿酸治疗且有随访者中16790例(25.7%)在启动后6个月内血尿酸≤360 μmol/L。
  • 中断时间序列分析显示,与大流行前相比,大流行期间降尿酸治疗处方略有改善,而血尿酸达标情况相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gout is the most prevalent inflammatory arthritis, yet one of the worst managed. Our objective was to assess how the COVID-19 pandemic impacted incidence and quality of care for people with gout in England, UK. METHODS: With the approval of National Health Service England, we did a population-level cohort study using primary care and hospital electronic health record data for 17·9 million adults registered with general practices using TPP health record software, via the OpenSAFELY platform. The study period was from March 1, 2015, to Feb 28, 2023. Individuals aged 18-110 years were defined as having incident gout if they were assigned index diagnostic codes for gout, were registered with TPP practices in England for at least 12 months before diagnosis, did not receive prescriptions for urate-lowering therapy more than 30 days before diagnosis, and had not been admitted to hospital or attended an emergency department for gout flares more than 30 days before diagnosis. Outcomes assessed were incidence and prevalence of people with recorded gout diagnoses, incidence of gout hospitalisations, initiation of urate-lowering therapy, and attainment of serum urate targets (≤360 μmol/L). FINDINGS: From a reference population of 17 865 145 adults, 246 695 individuals were diagnosed with incident gout. The mean age of individuals with incident gout was 61·3 years (SD 16·2). 66 265 (26·9%) of 246 695 individuals were female, 180 430 (73·1%) were male, and 189 035 (90·9%) of 208 050 individuals with available ethnicity data were White. Incident gout diagnoses decreased by 30·9% in the year beginning March, 2020, compared with the preceding year (1·23 diagnoses vs 1·78 diagnoses per 1000 adults). Gout prevalence was 3·07% in 2015-16, and 3·21% in 2022-23. Gout hospitalisations decreased by 30·1% in the year commencing March, 2020, compared with the preceding year (9·6 admissions vs 13·7 admissions per 100 000 adults). Of 228 095 people with incident gout and available follow-up, 66 560 (29·2%) were prescribed urate-lowering therapy within 6 months. Of 65 305 individuals who initiated urate-lowering therapy with available follow-up, 16 790 (25·7%) attained a serum urate concentration of 360 μmol/L or less within 6 months of urate-lowering therapy initiation. In interrupted time-series analyses, urate-lowering therapy prescribing improved modestly during the pandemic, compared with pre-pandemic, whereas urate target attainment was similar. INTERPRETATION: Using gout as an exemplar disease, we showed the complexity of how health care was impacted during the COVID-19 pandemic. We observed a reduction in gout diagnoses but no effect on treatment metrics. We showed how country-wide, routinely collected data can be used to map disease epidemiology and monitor care quality. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Russell MD, Massey J, Roddy E, et al. Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELY. Lancet Rheumatol. 2023. PMID: 38251486. doi:10.1016/S2665-9913(23)00206-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。